Agilon Health, Inc. (AGL) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AGL Revenue Growth
Revenue Breakdown (FY 2025)
AGL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
AGL Revenue Analysis (2019–2025)
As of May 8, 2026, Agilon Health, Inc. (AGL) generated trailing twelve-month (TTM) revenue of $5.82 billion, reflecting moderate decline in growth of -7.3% year-over-year. The most recent quarter (Q1 2026) recorded $1.42 billion in revenue, down 9.5% sequentially.
Looking at the longer-term picture, AGL's 5-year compound annual growth rate (CAGR) stands at +37.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $6.06 billion in 2024.
Revenue diversification analysis shows AGL's business is primarily driven by Medical Services (100%), and Other Operating (0%). With over half of revenue concentrated in Medical Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including CNC (+17.0% YoY), HUM (+14.1% YoY), and CVS (+7.6% YoY), AGL has underperformed the peer group in terms of revenue growth. Compare AGL vs CNC →
AGL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AGLCurrent | $5.8B | -7.3% | +37.2% | -7.1% | |
 CNC | $194.8B | +17.0% | +11.9% | -3.9% | |
 HUM | $129.7B | +14.1% | +10.9% | 1.1% | |
 CVS | $402.1B | +7.6% | +8.4% | 2.6% | |
 ELV | $199.1B | +9.4% | +10.3% | 4.1% | |
 MOH | $45.4B | +7.7% | +18.5% | 1.7% |
AGL Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5.93B | -2.1% | $-188,614,999 | -3.2% | $-421,076,000 | -7.1% |
| 2024 | $6.06B | +40.4% | $4.8M | 0.1% | $-292,130,000 | -4.8% |
| 2023 | $4.32B | +80.7% | $69.7M | 1.6% | $-232,133,000 | -5.4% |
| 2022 | $2.39B | +57.0% | $111.4M | 4.7% | $-105,378,000 | -4.4% |
| 2021 | $1.52B | +24.9% | $65.7M | 4.3% | $-372,242,000 | -24.5% |
| 2020 | $1.22B | +53.4% | $94.2M | 7.7% | $-56,673,000 | -4.7% |
| 2019 | $794.4M | - | $28.5M | 3.6% | $-106,574,000 | -13.4% |
See AGL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AGL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AGL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAGL — Frequently Asked Questions
Quick answers to the most common questions about buying AGL stock.
Is AGL's revenue growth accelerating or slowing?
AGL revenue declined -7.3% year-over-year, contrasting with the 5-year CAGR of +37.2%. TTM revenue fell to $5.8B. This reverses the prior growth trend.
What is AGL's long-term revenue growth rate?
Agilon Health, Inc.'s 5-year revenue CAGR of +37.2% reflects the variable expansion pattern. Current YoY growth of -7.3% is below this long-term average.
How is AGL's revenue distributed by segment?
AGL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.